Acute Myeloid Leukemia – Epidemiology – Mature Markets
DRG Epidemiology's coverage of acute myeloid leukemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute myeloid leukemia for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's acute myeloid leukemia forecast will answer the following questions:
· In developing countries, what impact will economic growth and development have on the number of people diagnosed with acute myeloid leukemia per year?
· How will improvements in survival change the number of people living with a diagnosis of acute myeloid leukemia?
· Of all people diagnosed with acute myeloid leukemia, how many in each country across the major mature pharmaceutical markets are drug-treated?
· How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of acute myeloid leukemia over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following acute myeloid leukemia subpopulations:
· Diagnosed incident cases by FLT3 mutation status
· 1st line drug-treatable population- AML (excluding APL)
· 2nd line drug-treatable population- AML (excluding APL)
· 3rd line drug-treatable population- AML (excluding APL)
· 1st line fit and unfit drug treatable population- AML (excluding APL)
· 1st line fit drug treated and non-drug treated population- AML (excluding APL)
· 1st line unfit drug treated and non-drug treated population- AML (excluding APL)
· 1st line drug treated and non-drug treated population- AML (excluding APL)
· 2nd line drug-treated and non-drug treated population- AML (excluding APL)
· 3rd line drug-treated and non-drug treated population- AML (excluding APL)
Note: coverage may vary by country and region.
Table of contents
- Acute Myeloid Leukemia - Epidemiology - Mature Markets
- Introduction
- Key Findings
- On-Demand Content
- Overview
- Diagnosed Incidence of Acute Myeloid Leukemia per 100,000 People of All Ages in 2019 and 2039ttttttttttttttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Acute Myeloid Leukemia over the Next 20 Yearsttttttttt
- Key Findings
- Methods
- Diagnosed Incident Cases
- Diagnosed Prevalent Cases
- FLT-3 Mutation
- Drug-Treatable Populations
- Drug-Treated Populations
- Lifetime DALYs Gained
- Epidemiology Data
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Acute Myeloid Leukemia
- Studies Excluded from the Analysis of Acute Myeloid Leukemia
- Risk/Protective Factors
- Risk/Protective Factors for Acute Myeloid Leukemia
- Bibliography
- Literature Review
- Introduction
Pramilesh Suryawanshi, M.P.H., is an associate epidemiologist at Clarivate. Previously, Mr. Suryawanshi worked with Pathfinder International in Lepra, the Netherlands Leprosy Relief Foundation, and the National Health Mission. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai, where he worked on several public health projects, including the assessment of social health insurance schemes. He holds a bachelor’s degree in the Indian system of medicine (Ayurveda) from Rajiv Gandhi University of Health Sciences in Karnataka.
Atul Sharma, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. He holds a master’s degree in public health from the School of Public Health, Post-Graduate Institute of Medical Education and Research, and a bachelor’s degree in dental surgery from MN DAV Dental College and Hospital.